Rapport Therapeutics, Inc. Common Stock

NASDAQ:RAPP

Biotechnology

Healthcare
$23.40 +0.05%

+$0.02 today

Market cap
$1.12B
Beta
0.98
P/E (TTM)
-16.2
EPS (TTM)
-$2.27
52W Low $10.51High $42.27

Volume 0.73M

Average 0.33M

RAPP Weighted Avg Shares (Diluted)

Average shares outstanding including dilutive securities, used to calculate diluted EPS.

Rapport Therapeutics, Inc. Common StockNASDAQ: RAPP

Weighted Avg Shares (Diluted) · Q1 FY2026 · quarter ended Mar 2026

Weighted avg shares (diluted) growth accelerates

Q1 FY2026 weighted avg shares (diluted) of 47.24M shares rose 144.9% year over year, ahead of the +115.2% change in trailing-twelve-month weighted avg shares (diluted). Sequentially, it rose 0.6% from the prior quarter. Over 3 fiscal years it compounded at +32.7% a year.

Context

  • Weighted avg shares (diluted) increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +144.9% holds above the trailing-twelve-month pace of +115.2%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
47.24M+0.6% QoQ
Last fiscal yearDec 2025
46.98M+126.5% YoY
LTMMar 2026
41.9M+115.2% YoY
Weighted Avg Shares (Diluted) past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+144.9%——
1 year+126.5%——
3-year CAGR+32.7%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares (Diluted) history

Shares · from the income statement

Latest · FY2025
46.98M USD
Year-over-year change
+126.5%
3-year CAGR
+32.7%

Weighted Avg Shares (Diluted) vs competitors

How RAPP compares with its peers on the latest reported figures

  • RAPP's LTM Mar 2026 weighted avg shares (diluted) of 41.9M shares is the 6th highest of the 10 companies compared; the peer median is 43.04M shares.
  • Its year-over-year change of +115.2% is the highest of 9, against a peer median of +7.3%.
  • Over three fiscal years its annual growth of +32.7% compares with a peer median of +4.1%.
RAPP Competitors Peer median
Weighted Avg Shares (Diluted) for RAPP and competitors
Company Period LTM YoY 3-year CAGR
ACADACADIA Pharmaceuticals Inc.LTM Sep 2026173.1M +2.8%+2.0%
NMRANeumora Therapeutics, Inc. Common StockLTM Mar 2026166.7M +4.0%+2.4%
CGTXCognition Therapeutics, Inc.LTM Mar 202679.93M +69.4%+35.9%
AXSMAxsome Therapeutics, Inc.LTM Jun 202650.84M +4.3%+7.0%
MPLTMapLight Therapeutics, Inc.LTM Mar 202643.04M +3.9%+2.0%
RAPPRapport Therapeutics, Inc. Common StockLTM Mar 202641.9M +115.2%+32.7%
CTNMContineum Therapeutics, Inc. Class A Common StockLTM Mar 202630.55M +18.4%+3.3%
ANROAlto Neuroscience, Inc.LTM Mar 202629.75M +10.2%+4.1%
PRAXPraxis Precision Medicines, Inc.LTM Sep 202627.42M +29.8%+94.2%
LBRXLB Pharmaceuticals Inc Common StockLTM Mar 202619.77M —+92.6%
SPTXSeaport Therapeutics, Inc. Common Stock—— ——
Peer median (excluding RAPP) 43.04M+7.3%+4.1%

Competitors are the stored peer set for RAPP. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue0000
Cost of Revenue15K112K839K1.02M
Gross Profit(15K)(112K)(839K)(1.02M)
Gross Margin————
Research & Development9.12M28M60.94M94.79M
Selling, General & Admin1.37M8.07M22.12M30.31M
Operating Expenses10.35M36.07M82.22M125.1M
Depreciation & Amortization15K112K839K1.02M
EBITDA(10.35M)(34.66M)(77.47M)(124.08M)
EBITDA Margin————
Operating Income(10.37M)(36.18M)(83.06M)(125.1M)
Operating Margin————
Interest Income02.53M12.14M13.62M
Interest Expense285K000
Other Income / Expenses(285K)1.4M4.75M13.62M
Income Before Tax(10.65M)(34.78M)(78.31M)(111.48M)
Pre-Tax Margin————
Income Tax Expense010K00
Net Income(10.65M)(34.79M)(78.31M)(111.48M)
Net Margin————
EPS (Basic)(0.29)(0.95)(3.78)(2.86)
EPS (Diluted)(0.29)(0.95)(3.78)(2.86)
Weighted Avg Shares20.12M18.08M20.74M46.98M
Weighted Avg Shares (Diluted)20.12M18.08M20.74M46.98M

Rapport Therapeutics, Inc. Common Stock

NASDAQ:RAPP

Intrinsic Alpha fair value

Locked

Current Price

$23.40

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.